Howlett Sarah, Carter Thomas J, Shaw Heather M, Nathan Paul D
Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
University College London Hospital, London, UK.
Ther Adv Med Oncol. 2023 Mar 21;15:17588359231160140. doi: 10.1177/17588359231160140. eCollection 2023.
Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM.
替贝福单抗是一种一流的免疫治疗药物，它包含一种经过工程改造的T细胞受体，该受体靶向由人类白细胞抗原-A*02:01细胞呈递的gp100表位，并与抗CD3单链可变片段融合。替贝福单抗既是首个在晚期实体癌治疗中显示出疗效的双特异性T细胞衔接器，也是首个在葡萄膜黑色素瘤（UM）患者中证明具有总生存获益的抗癌治疗药物。这篇综述文章将重点关注替贝福单抗的临床开发、作用机制以及晚期UM治疗管理的相应演变。
